Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

AQST announced favorable human factors and pharmacokinetic data for Anaphylm™, a sublingual film formulation of dibutepinephrine intended for anaphylaxis treatment. The company plans to resubmit the New Drug Application (NDA) in Q3 2026, following previous regulatory feedback. This represents meaningful progress toward a potential commercial launch in the emergency care market.

The revised packaging design demonstrates substantial operational improvements: median time to open the pouch decreased from 17 seconds to 3 seconds, while incorrect film placement errors fell by over 80%. These usability enhancements address critical real-world administration concerns in acute anaphylaxis scenarios, where rapid, reliable self-administration is clinically essential. Self-administered pharmacokinetic profiles matched clinician-administered results, supporting the auto-administration use case.

The top-of-tongue PK arm showed clinically meaningful pharmacodynamic outcomes, validating the sublingual delivery mechanism for rapid systemic absorption. These data reduce regulatory and commercial execution risk ahead of the planned resubmission, though approval timelines remain uncertain and competitive pressures from established epinephrine autoinjectors persist.

Sector implication: This represents a late-stage clinical advancement in specialty pharmaceuticals within the emergency care niche. Success would diversify AQST's portfolio and create new revenue streams, but valuation impact depends on approval probability and market penetration assumptions relative to incumbent competitors.